UroGen Pharma Ltd. (URGN) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: 25.26
30Y Low3.8·High25.3
ROE
N/A
—
5yr avg: -211.6%
30Y Low-212%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
URGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
UroGen Pharma Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.1B | $457M | $433M | $202M | $213M | $392M | $685M | $678M | $362M | — |
| Enterprise Value | $1.3B | $1.1B | $408M | $437M | $246M | $169M | $341M | $638M | $577M | $325M | — |
| P/E Ratio → | -8.34 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 11.79 | 10.26 | 5.05 | 5.23 | 3.14 | 4.42 | 33.26 | 38057.98 | 601.40 | 44.32 | — |
| P/B Ratio | — | — | — | — | — | 25.26 | 4.07 | 3.80 | 7.53 | 5.28 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
URGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.42 | 4.51 | 5.28 | 3.82 | 3.51 | 28.91 | 35442.20 | 511.58 | 39.78 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
URGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
UroGen Pharma Ltd. earns an operating margin of -113.7%. Operating margins have compressed from -79.2% to -113.7% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.7% | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% | 100.0% | -59.8% | 92.6% | 99.8% |
| Operating Margin | -113.7% | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1074.2% | -608211.1% | -6842.2% | -244.5% | 4.6% |
| Net Profit Margin | -139.8% | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% | -1088.9% | -584144.4% | -6707.2% | -245.2% | -11.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -211.6% | -92.9% | -77.8% | -95.4% | -47.2% | -11.6% |
| ROA | -63.1% | -63.1% | -54.7% | -65.1% | -86.0% | -91.7% | -79.2% | -68.7% | -84.5% | -40.6% | -9.1% |
| ROIC | — | — | — | — | — | -1466.7% | -106.7% | -134.6% | -570.5% | -113.1% | — |
| ROCE | -63.4% | -63.4% | -50.0% | -50.6% | -75.6% | -93.3% | -89.4% | -80.2% | -97.3% | -45.1% | 4.3% |
URGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $18M ($128M total debt minus $111M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.05 | 0.02 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -5.23 | -0.53 | -0.26 | -1.12 | -0.54 | -1.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | -21.13 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -6.11 |
| Interest Coverage | -4.08 | -4.08 | -7.64 | -4.22 | -9.25 | — | -349.45 | -385.49 | — | — | — |
URGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
UroGen Pharma Ltd.'s current ratio of 4.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.65x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.42x to 4.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.01 | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 | 5.39 | 7.63 | 7.59 | 10.59 | 7.03 |
| Quick Ratio | 3.65 | 3.65 | 5.81 | 5.24 | 5.21 | 4.90 | 5.30 | 7.63 | 7.59 | 10.54 | 6.99 |
| Cash Ratio | 2.60 | 2.60 | 5.15 | 4.39 | 4.18 | 3.98 | 4.76 | 7.55 | 7.52 | 10.38 | 6.81 |
| Asset Turnover | — | 0.55 | 0.32 | 0.46 | 0.47 | 0.40 | 0.10 | 0.00 | 0.01 | 0.11 | 0.76 |
| Inventory Turnover | 0.76 | 0.76 | 0.96 | 1.65 | 1.77 | 1.07 | 0.51 | — | — | 1.90 | 0.27 |
| Days Sales Outstanding | — | 109.98 | 81.97 | 68.15 | 72.05 | 89.02 | 218.00 | — | — | — | 1.73 |
URGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
UroGen Pharma Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $48M | $43M | $29M | $23M | $22M | $22M | $21M | $16M | $10M | $12M |
Peer Comparison
Compare URGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 URGNYou | $1B | -8.3 | — | — | 88.7% | -113.7% | — | — | — |
 PCVX | $7B | -9.1 | — | — | — | — | -25.6% | -24.2% | — |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 CRVS | $1B | -27.5 | — | — | — | — | -32.6% | -78.1% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 JNJ | $536B | 38.4 | 18.6 | 27.0 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See URGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs URGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare URGN vs PCVX
Side-by-side business, growth, and profitability comparison vs Vaxcyte, Inc..
Start ComparisonURGN — Frequently Asked Questions
Quick answers to the most common questions about buying URGN stock.
What is UroGen Pharma Ltd.'s P/E ratio?
UroGen Pharma Ltd.'s current P/E ratio is -8.3x. This places it at the 50th percentile of its historical range.
Is URGN stock overvalued?
Based on historical data, UroGen Pharma Ltd. is trading at a P/E of -8.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are UroGen Pharma Ltd.'s profit margins?
UroGen Pharma Ltd. has 88.7% gross margin and -113.7% operating margin.